Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis.

Immunotargets Ther · 2015 · PMC4918256 · PMID 27471722

Europe PMC DOI

hedged sentence

0.3700

closest p · 7.4× alpha

0.3700

boldest claim

The sentences

did not reach statistical significanceP =0.37not close (p > 0.1)

The cumulative survival of patients without ESRD or relapse was 58% in the rituximab group compared to 73% in the control group, and this did not reach statistical significance ( P =0.37).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.